Since S100A9 inhibition alone using tasquinimod is not sufficient to eliminate tumors despite reduced tumor growth and metastasis in vivo, we next evaluated the ability of tasquinimod to sensitize tumors to cisplatin chemotherapy. This evidence concerns the gene S100A9 and neoplasm.